Table 1 The clinical trials for drugs targeting Drp1
NCT number | Phases | Enrollment | Study status | Interventions/Treatments | Conditions/Diseases |
|---|---|---|---|---|---|
NCT02966665 | Phase 1 | 420 | Recruiting | MitoQ, BQ-123, BH4/acetylcholine, sodium nitroprusside, angiotensin-II, norepinephrine, phentolamine/angiotensin-II, valsartan/fexofenadine, ranitidine/BQ-123/BH4, L-NMMA, vitamin C, vitamin E, α-lipoic acid and L-ascorbate/maximum exercise | Chronic obstructive pulmonary disease, pulmonary artery hypertension, heart failure, hypertension |
NCT04276740 | Phase 2 | 206 | Not yet recruiting | MitoQ/placebo | Ulcerative colitis flare |
NCT00329056 | Phase 2 | 128 | Completed | MitoQ | Parkinson's disease |
NCT03586414 | NA | 60 | Recruiting | MitoQ, then placebo/placebo, then MitoQ | Diastolic dysfunction |
NCT04267926 | Phase 1/Phase2 | 60 | Recruiting | 20Â mg MitoQ/40Â mg MitoQ/placebo | Multiple sclerosis, fatigue |
NCT03166800 | Phase 1/Phase 2 | 9 | Terminated | MitoQ/placebo | Multiple Sclerosis, Fatigue |
NCT04098510 | NA | 10 | Unknown | MitoQ | Healthy |
NCT04109820 | NA | 15 | Recruiting | MitoQ | Sickle cell disease |
NCT03506633 | NA | 13 | Recruiting | MitoQ | Peripheral arterial disease, peripheral artery disease |
NCT04026711 | Phase 1 | 40 | Recruiting | MitoQ/placebo oral tablet | Asthma, obesity |
NCT05539625 | Phase 2 | 120 | Not yet recruiting | MitoQ/placebo | Ulcerative colitis |
NCT05561556 | NA | 60 | Recruiting | MitoQ | Cardiovascular diseases, hypertension, racism, vascular diseases |
NCT05686967 | Phase 1 | 50 | Recruiting | MitoQ/placebo/aerobic exercise | Aging, menopause |
NCT02597023 | NA | 55 | Completed | MitoQ/placebo | Aging |
NCT05872139 | NA | 23 | Completed | MitoQ/placebo | Aging, endothelial dysfunction, cardiovascular function, arterial stiffness |
NCT04851288 | Phase 2 | 112 | Recruiting | MitoQ/placebo | Aging |
NCT04334135 | NA | 60 | Recruiting | MitoQ | Racial disparities, blood pressure, cardiovascular risk factor, renal function |
NCT02364648 | Phase 4 | 24 | Unknown | MitoQ/placebo | Chronic kidney disease |
NCT05605548 | NA | 24 | Recruiting | MitoQ/placebo | Chronic obstructive pulmonary disease |
NCT03960073 | NA | 25 | Completed | MitoQ/placebo | Renal insufficiency, chronic, heart failure with preserved ejection fraction |
NCT05146843 | NA | 44 | Not yet recruiting | MitoQ/placebo | Breast neoplasms |
NCT04558190 | NA | 10 | Completed | MitoQ/salbutamol/intralipid, 20% intravenous emulsion | Insulin resistance |
NCT05410873 | Phase 2 | 106 | Recruiting | MitoQ/placebo | Dilated cardiomyopathy |
NCT00433108 | Phase 2 | 30 | Completed | MitoQ | Chronic hepatitis C |
NCT05381454 | Phase 1/Phase 2 | 80 | Completed | MitoQ | Respiratory viral infection, antiviral treatment, COVID-19 |
NCT01167088 | Phase 2 | 110 | Terminated | MitoQ/placebo | Non-alcoholic fatty liver disease |
NCT05373043 | NA | 300 | Recruiting | MitoQ/placebo | Long-COVID |
NCT05886816 | Phase 2 | 112 | Not yet recruiting | MitoQ/placebo | SARS-CoV infection, COVID-19 |
NCT02690064 | NA | 13 | Active not recruiting | Acute antioxidant/chronic antioxidant/placebo | Cystic fibrosis |